Olga Varea Abbad

Biomedical scientist with more than fifteen years of experience in research. Over the years, I have demonstrated adaptability to different environments with productivity and results. Main interests are to help understand complex human diseases and to contribute to develop strategies for an early detection which is determinant to obtain the maximum benefit of a potential therapeutic strategy in patients.

• Project Coordinator at CaixaResearch project in an international work team.
• Project leader at Northwestern University of Chicago, IL, USA
• Scientific publications and conferences at international congresses

• FENS, Federation of European Neuroscience Societies (2008, 2013, 2024). Posters presentation.
• SETGyC, Pamplona (2023). Poster presentation.
• MultiBrain Congress, Barcelona (2023)
• Lafora disease international congress (2017-2021). Oral communication. Barcelona (2017), San Diego (2018), Alcalá de Henares (2019), Zoom meeting (2020). Conferences in San Diego, Alcalá de Henares and Zoom meeting.
• SfN, Society for Neuroscience (Washington 2009, Washington 2021, New Orleans 2022). Poster presentation.

• Varea O., Duran J. and Guinovart J. Malin restoration as a proof of concept for gene therapy for Lafora disease. Brain Communications, 2022.
• Martin-de-Saavedra MD., Dos Santos M., Varea O. et al. Shed Cntnap2 ectodomain is detectable in CSF and regulates Ca2+ homeostasis and network synchrony via PMCA2/ATP2B2. Neuron, 2022.
• Pellegrini P., Hervera A., Varea O. et al. Lack of p62 impairs glycogen aggregation and exacerbates pathology in a mouse model of myoclonic epilepsy of Lafora. Biorxive. Submitted. 2021.
• Duran J., Hervera A., Markussen KH., Varea O., LopezSoldado I., Sun RC., Del Río JA., Genntry MS., Guinovart JJ. Astrocytic glycogen accumulation drives the pathophysiology of neurodegeneration in Lafora disease. Brain, 2021.
• Varea O., Duran J., Aguilera M., Prats N., Guinovart JJ. Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity. Neurobiology of disease, 147: 105173. 2020.
• Duran J., Gruart A., Varea O., López-Soldado I., DelgadoGarcía JM., Guinovart JJ. Lack of Neuronal Glycogen Impairs Memory Formation and Learning-Dependent Synaptic Plasticity in Mice. Front Cell Neuroscience. 13:374. 2019.
• Lopez LC., Varea O., Navarro S., Carrodeguas JA., Sanchez de Groot N., Ventura S., Sancho J. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. International Journal of Molecular Science.2016.
• Varea O., Kopeikina K, Martin-Saavedra MD, Shurmann B, Flemming H, Fawcett J, Eujoon K, Swanson GT, Penzes P.. Synaptic abnormalities and glutamate receptor accumulation in cytoplasmic aggregates in Cntnap2 knockout neurons. Proc.Natl. Acad. Sci.USA. 112 (19):617681. 2015.
• Varea O, Escoll M, Diez H, Garrido JJ, Wandosell F. Oestradiol signalling through the Akt-mTORC1-S6K1. Biochim Biophys Acta. 1833(5):1052-64. 2013.
• Wandosell F., Varea O, MA Arevalo, LM Garcia-Segura. Oestradiol regulates ẞ-catenin-mediated transcription in neurons. Journal of Neuroendocrinology; 24 (1):194-4. 2011.
• Varea O, Arevalo MA, Garrido JJ, Garcia-Segura LM, Wandosell F, Mendez P. Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Steroids. 75(8-9):565-9. 2009.
• Garrido JJ, Simon D, Varea O, Wandosell F. GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett 581:1579-1586. 2007.
• Simon D., Varea O., Garrido JJ., Wandosell F. Role of GSK3/Shaggy in Neuronal Cell Biology. Book chapter: ¨Glycogen synthase kinase 3 (GSK3) and its inhibitors: Drug discovery and development. pp45-66. Editorial: Wiley-Interscience.

AQU lector, Acreditación de profesorado